Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral)-Global Forecast to 2030

The vaccines market is expected to reach 63.66 billion USD in 2030, up from 50.46 billion USD in 2025, growing at a CAGR of 4.8% during the forecast period. Factors such as the high incidence of contagious diseases, innovation in vaccine technology, government support and substantial funding for vaccine development, increasing vaccination initiatives, and a strong focus on investing in and launching innovative products are driving this growth vaccines.

In 2024, by disease indication, the pneumococcal segment accounted for the largest share of the vaccines market.

Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, and other disease indications. In 2022, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits outcomes.

In 2024, by type, the multivalent vaccines segment accounted for the largest share of the vaccines market.

The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2024, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance comes from the ability of multivalent vaccines to provide protection against multiple diseases with a single dose—simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.

In 2024, the Asia Pacific was the fastest growing region in the Vaccines market.

The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public–private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region’s large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific’s leadership in the vaccine industry market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25%
• By Region: North America -35%, Europe - 25%, Asia Pacific -20%, Latin America -10%, the Middle East & Africa- 10%

GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi fei Biological (China), Indian Immunologicals Ltd (India) are some of the key companies offering Vaccines.

Research Coverage

This research report categorizes the Vaccines market by technology (conjugate vaccine, recombinant vaccine, inactivated & subunit vaccine, live attenuated vaccine, toxoid vaccine, viral vector vaccine, mRNA vaccine, and other vaccines), type (monovalent vaccines, multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccine, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSA, other disease indications), route of administration (intramuscular & subcutaneous, oral, other routes), end user (pediatric vaccines, adult vaccines), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. Competitive analysis of top players and upcoming startups within the vaccines market ecosystem is included in this report. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.

Key Benefits of Buying the Report

This report offers a comprehensive overview of the Vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.

The report provides insights into the following pointers:

Analysis of key drivers (strong emphasis on investment and launch of novel vaccines, rising prevalence of infectious disease, expanding immunization programs, advancements in vaccine technology and robust government support & funding for the development of vaccines), restraints (High development cost, patent expiry ), opportunities (Increased focus on therapeutic vaccines, robust & strong pipeline) and challenges (Stringent regulatory processes, vaccine supply shortage, frequent product recall)

• Product Development/Innovation: Detailed insights on newly launched Products, and technological assessment of the Vaccines market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Vaccines market across varied regions.
• Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Vaccines market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi fei Biological (China), Indian Immunologicals Ltd (India), among others, in the vaccines market. The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments, and funding activities, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines sector market. Show more